• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺结核患者血清KL-6水平的评估。

Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis.

作者信息

Inoue Y, Nishimura K, Shiode M, Akutsu H, Hamada H, Fujioka S, Fujino S, Yokoyama A, Kohno N, Hiwada K

机构信息

Second Department of Internal Medicine, Ehime University School of Medicine, Japan.

出版信息

Tuber Lung Dis. 1995 Jun;76(3):230-3. doi: 10.1016/s0962-8479(05)80010-3.

DOI:10.1016/s0962-8479(05)80010-3
PMID:7548906
Abstract

SETTING

KL-6, a human MUC-1 mucin preferentially expressed on type II pneumocytes, is a sensitive serum marker for evaluating alveolar damage of interstitial pneumonia and pulmonary fibrosis. Some patients with pulmonary tuberculosis develop severe respiratory dysfunction caused by extensive pulmonary fibrosis, compensatory emphysema and fibrous pleural thickening.

OBJECTIVE

To evaluate the clinico-pathological significance of KL-6 in pulmonary tuberculosis.

DESIGN

Serum KL-6 levels were measured in sera from 57 patients with active pulmonary tuberculosis and 38 healthy controls by a sandwich-type enzyme-linked immunosorbent assay. Immunohistochemistry was performed by an avidin-biotin-peroxidase complex method.

RESULTS

KL-6 levels were significantly higher in the patients than in the healthy controls (518 +/- 693 [SD] vs 227 +/- 91 U/ml, P < 0.001) and increased significantly according to the extent of pulmonary lesions evaluated by chest X-ray (P < 0.001). There was a significant negative correlation between serum KL-6 levels and % vital capacity (VC) (r = 0.642, P < 0.05). KL-6 was strongly expressed on proliferated type II pneumocytes and cuboidal epithelial cells adjacent to thickened intralobular septa and pleura.

CONCLUSIONS

In pulmonary tuberculosis, serum KL-6 originates from proliferated type II pneumocytes and cuboidal epithelial cells, and is a useful marker presenting the degree and extent of pulmonary fibroproductive lesions.

摘要

背景

KL-6是一种在II型肺细胞上优先表达的人MUC-1粘蛋白,是评估间质性肺炎和肺纤维化肺泡损伤的敏感血清标志物。一些肺结核患者会因广泛的肺纤维化、代偿性肺气肿和纤维性胸膜增厚而出现严重的呼吸功能障碍。

目的

评估KL-6在肺结核中的临床病理意义。

设计

采用夹心型酶联免疫吸附测定法检测57例活动性肺结核患者和38例健康对照者血清中的KL-6水平。采用抗生物素蛋白-生物素-过氧化物酶复合物法进行免疫组织化学检测。

结果

患者的KL-6水平显著高于健康对照者(518±693[标准差]对227±91 U/ml,P<0.001),并根据胸部X线评估的肺部病变程度显著升高(P<0.001)。血清KL-6水平与肺活量(VC)百分比之间存在显著负相关(r=0.642,P<0.05)。KL-6在增生的II型肺细胞以及小叶内间隔和胸膜增厚处相邻的立方上皮细胞上强烈表达。

结论

在肺结核中,血清KL-6来源于增生的II型肺细胞和立方上皮细胞,是反映肺纤维增生性病变程度和范围的有用标志物。

相似文献

1
Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis.肺结核患者血清KL-6水平的评估。
Tuber Lung Dis. 1995 Jun;76(3):230-3. doi: 10.1016/s0962-8479(05)80010-3.
2
Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.血清KL-6水平作为评估系统性硬化症患者肺纤维化的有用标志物。
J Rheumatol. 2000 Apr;27(4):930-4.
3
[Immunohistochemical study of KL-6 in pulmonary tuberculosis].
Nihon Kokyuki Gakkai Zasshi. 2001 Aug;39(8):553-8.
4
Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis.血清KL-6用于评估结节病活动期肺炎。
Chest. 1996 May;109(5):1276-82. doi: 10.1378/chest.109.5.1276.
5
Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis.伴有多发性肌炎/皮肌炎的间质性肺炎患者血清中KL-6的连续变化
Ann Rheum Dis. 2000 Apr;59(4):257-62. doi: 10.1136/ard.59.4.257.
6
Serum KL-6 levels in patients with pulmonary complications after allogeneic bone marrow transplantation.异基因骨髓移植后肺部并发症患者的血清KL-6水平
Int J Hematol. 2001 Dec;74(4):464-8. doi: 10.1007/BF02982094.
7
Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia.间质性肺炎和肺泡肺炎患者循环中KL-6、III型前胶原N端肽及IV型胶原7S的比较研究
Respir Med. 1997 Oct;91(9):558-61. doi: 10.1016/s0954-6111(97)90090-1.
8
KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases.KL-6作为结缔组织病中间质性肺炎活动的一种新型标志物。
Rheumatol Int. 2000;19(6):223-5. doi: 10.1007/s002960000064.
9
Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis.血清KL-6水平作为肺泡蛋白沉积症患者的监测指标。
Thorax. 1998 Sep;53(9):809-11. doi: 10.1136/thx.53.9.809.
10
Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis.
Lung Cancer. 2001 Oct;34(1):141-8. doi: 10.1016/s0169-5002(01)00215-x.

引用本文的文献

1
Association of Serum Krebs von den Lungen-6 (KL-6) Levels and Disease Severity in Patients Hospitalized with COVID-19.新型冠状病毒肺炎住院患者血清肺表面活性物质相关蛋白A(KL-6)水平与疾病严重程度的相关性
Infect Dis Clin Microbiol. 2023 Dec 29;5(4):292-299. doi: 10.36519/idcm.2023.260. eCollection 2023 Dec.
2
Serum KL-6 levels predict clinical outcomes and are associated with polymorphism in Japanese patients with COVID-19.血清 KL-6 水平可预测临床结局,并与日本 COVID-19 患者的多态性相关。
BMJ Open Respir Res. 2023 May;10(1). doi: 10.1136/bmjresp-2023-001625.
3
Progress in the diagnosis of ocular sarcoidosis.
眼结节病的诊断进展。
Indian J Ophthalmol. 2022 Apr;70(4):1121-1129. doi: 10.4103/ijo.IJO_2830_21.
4
The Potential of Lung Epithelium Specific Proteins as Biomarkers for COVID-19-Associated Lung Injury.肺上皮特异性蛋白作为新型冠状病毒肺炎相关肺损伤生物标志物的潜力
Diagnostics (Basel). 2021 Sep 8;11(9):1643. doi: 10.3390/diagnostics11091643.
5
Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者慢性肺部感染的发病率和病因。
PLoS One. 2020 Apr 3;15(4):e0230746. doi: 10.1371/journal.pone.0230746. eCollection 2020.
6
Sequential changes of serum KL-6 predict the progression of interstitial lung disease.血清KL-6的连续变化可预测间质性肺疾病的进展。
J Thorac Dis. 2018 Aug;10(8):4705-4714. doi: 10.21037/jtd.2018.07.76.
7
Early control of Mycobacterium tuberculosis infection requires il12rb1 expression by rag1-dependent lineages.早期控制结核分枝杆菌感染需要 rag1 依赖性谱系表达 il12rb1。
Infect Immun. 2012 Nov;80(11):3828-41. doi: 10.1128/IAI.00426-12. Epub 2012 Aug 20.
8
Update on the diagnosis and treatment of Pneumocystis pneumonia.关于肺孢子菌肺炎的诊断和治疗的最新进展。
Ther Adv Respir Dis. 2011 Feb;5(1):41-59. doi: 10.1177/1753465810380102. Epub 2010 Aug 24.
9
Clinical use of biomarkers of survival in pulmonary fibrosis.肺纤维化中生存生物标志物的临床应用。
Respir Res. 2010 Jun 28;11(1):89. doi: 10.1186/1465-9921-11-89.
10
Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis.肺结核患者细胞因子分泌差异及早期治疗反应
Clin Exp Immunol. 2009 Apr;156(1):69-77. doi: 10.1111/j.1365-2249.2009.03875.x. Epub 2009 Jan 22.